Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its ...

6 analysts have shared their evaluations of Insulet (NASDAQ: PODD) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below provides a snapshot of their ...

New 100 mg/dL Target Glucose setting offers more customization and tighter glucose management. Enhanced algorithm helps users remain in Automated Mode to improve the user experience. Most requested ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...

As of May 6, 2025, the average one-year price target for Insulet is $323.11/share. The forecasts range from a low of $263.72 to a high of $367.50. The average price target represents a decrease of ...

Insulet ((PODD)) has held its Q3 earnings call. Read on for the main highlights of the call. Insulet’s recent earnings call paints a picture of robust performance and strategic growth, marked by ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...

Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Flavia Pease will ...

Insulet Corporation PODD reported third-quarter 2025 adjusted earnings per share (EPS) of $1.24, up 37.8% from the year-ago period’s figure. The bottom line surpassed the Zacks Consensus Estimate by 9 ...